IL17A and psoriasis: Preliminary reports support the use of 2 anti-IL17 A agents, secukinumab and ixekizumab in EP patients, emphasizing the rapidity of action and achievement of a satisfactory long-term clinical response.6, 7, 8 Interleukin 17A is a pro-inflammatory cytokine secreted by Th17 cells, natural killer cells, mast cells, and neutrophils, and plays a crucial role in severe widespread psoriasis.9